Episodes
Friday Sep 22, 2023
Friday Sep 22, 2023
More than 46 million people in the US met diagnostic criteria for a substance use disorder (SUD) in 2021. These numbers are staggering and suggest that SUD is more common than diabetes in the United States. However, only 6% received treatment. Expanding the care delivery model is essential to improving treatment access and enhancing physical, mental, and social/societal outcomes. Pharmacists can play a key role.
Guest Authors: Melissa C. Palmer, PharmD, BCPS, BCPP and Amanda Stahnke, PharmD, BCACP
Music by Good Talk
Friday May 26, 2023
Is MBSR* as Good as Meds for Anxiety Disorders?
Friday May 26, 2023
Friday May 26, 2023
One in five people in the U.S. report suffering from anxiety in the past year, and one in three will experience an anxiety disorder in their lifetime, but 40% of patients go untreated. Perhaps patients are disinterested (or distrust) in traditional pharmacotherapy ... or perhaps it is due to a lack of availability of services (like cognitive behavioral therapy – CBT). Many patients (and clinicians) are interested in exploring and using alternative treatment approaches, but are they effective?
Guest Authors: Cindy King, PharmD, BCACP and Chris Paxos, PharmD, BCPP, BCPS, BCGP
Music by Good Talk
*MBSR = Mindfulness-base Stress Reduction
Friday Mar 17, 2023
Complex Patient Case 2 - Managing Adverse Effects
Friday Mar 17, 2023
Friday Mar 17, 2023
Reason for Visit: The patient is here today for hypotension and diabetes follow-up. The primary care physician has consulted the clinical pharmacist regarding hypotension.
Chief Complaint: “I feel dizzy when I stand up and feel like my heart is racing. I have never passed out, but it feels like I might, and I usually have to sit back down."
Guest Authors: Kellie Ball, PharmD and Johnathon Proctor, PharmD
Expert Panelists: Morgan Weaver Godfrey, PharmD, BCPS and Richard J. Silvia, PharmD, BCPP
Thursday Feb 09, 2017
Helpful, Harmful, or Futile — Antidepressant Use in Patients with Heart Failure
Thursday Feb 09, 2017
Thursday Feb 09, 2017
About 5 million Americans are currently living with heart failure (HF) and an astounding 24-42% also suffer from depression. One meta-analysis found a greater than 2-fold risk of death in patients with HF and comorbid depression. Depressed patients with HF are more likely to be hospitalized, seek care from emergency rooms, and rack up big bills. Not surprisingly, patients with HF and depression have a much lower quality of life when compared to HF patients without depression. Clearly, this is BIG problem. But can we do anything about it?
Theme Music by Good Talk
Tuesday Aug 16, 2016
Tuesday Aug 16, 2016
Persons diagnosed with a psychiatric disorder consume nearly half of all cigarettes smoked in the United States! Seven first-line therapies have shown to increase long-term abstinence rates, with bupropion sustained release (SR) doubling and varenicline tripling the odds of quitting. However, the FDA issued black box warnings in 2009 regarding increased neuropsychiatric events and suicidality with bupropion and varenicline use. Thus many clinicians have been reluctant to prescribe these agents in persons with mental illness. The EAGLES study compared the efficacy of non-nicotine therapies to nicotine replacement therapy in smokers with mental illness